Vircell Microbiologists

Vircell Microbiologists is a Spanish biotechnology company based in Granada, founded in 1991. It specializes in the development, manufacturing and commercialization of in vitro diagnostic (IVD) reagents and molecular solutions for human infectious diseases. The company operates through two main lines: Vircell Microbiologists, which provides ready-to-use reagents for serological techniques, and Vircell Molecular, which offers real-time PCR kits and independent molecular controls for a wide range of infectious diseases. With more than 30 years of experience, Vircell has built a portfolio covering immunofluorescence, ELISA, rapid tests and molecular biology. Its products address clinically important pathogens such as Helicobacter pylori, Mycobacterium tuberculosis and Aspergillus, among others. The company emphasizes non-invasive diagnostic solutions, automated detection and early diagnosis to support laboratories worldwide. Vircell was founded in Granada in 1991 as a biotechnology company focused on human infectious disease diagnosis. From its early years, it combined in-house development, internal manufacturing and an international outlook, with initial products centered on cell culture and immunofluorescence. During the 1990s, it began international expansion and developed Brucellacapt®, a solution for the diagnosis of chronic brucellosis that became an international reference for chronic forms of Malta fever. Between 2000 and 2009, Vircell expanded its technical capabilities in ELISA, immunofluorescence, rapid tests and molecular biology. In 2005, it launched AMPLIRUN®, a line of molecular controls for PCR designed to help laboratories improve precision, reliability and standardization of nucleic acid amplification techniques. This positioned the company as a trusted partner for clinical laboratories, research centers and international diagnostic entities. From 2010 onward, Vircell entered a phase of international scale-up, new facilities and commercial consolidation. Today it serves laboratories around the world with a global network and specialized scientific and technical support, maintaining its headquarters in Granada, Spain. The company remains privately held and continues to focus on infectious disease diagnostics.

Vircell Microbiologists was founded in Granada, Spain, in 1991 as a biotechnology company specialized in the diagnosis of human infectious diseases. From its beginnings, the company combined in-house development, internal manufacturing and an international vocation, with products focused on cell culture and immunofluorescence. This initial stage laid the foundations for its specialization in clinical microbiology and infectious disease diagnosis. During these years, Vircell also began its expansion outside Spain and developed Brucellacapt®, a solution for the diagnosis of chronic brucellosis that became an international reference for the diagnosis of chronic forms of Malta fever. Between 2000 and 2009, Vircell expanded its technical capabilities in ELISA, immunofluorescence, rapid tests and molecular biology, reinforcing its role as a provider of solutions for infectious disease diagnosis. In 2005, the company took a key step with the development of AMPLIRUN®, a line of molecular controls for PCR designed to help laboratories improve the precision, reliability and standardization of their nucleic acid amplification techniques. This advance positioned Vircell as a trusted partner for clinical laboratories, research centers and international diagnostic entities. From 2010 onward, Vircell entered a phase of international scale-up, new facilities and commercial consolidation. The company continued to develop and commercialize diagnostic solutions, maintaining a focus on infectious diseases. Today, with more than 30 years of experience, Vircell operates through two main lines: Vircell Microbiologists, offering ready-to-use reagents for serological techniques, and Vircell Molecular, providing real-time PCR kits and independent molecular controls for a broad range of infectious diseases. The company has a global presence with specialized scientific and technical support to help laboratories implement and optimize diagnostic processes.

• 2010

  Entered a phase of international scale-up, new facilities and commercial consolidation.

• 2005

  Developed AMPLIRUN®, a line of molecular controls for PCR.

• 1991

  Vircell founded in Granada, Spain, as a biotechnology company specialized in human infectious disease diagnosis.

• 1990

  Began international expansion and developed Brucellacapt®, a reference for chronic brucellosis diagnosis.

Specialist in immunoassay and molecular diagnostics for infectious diseases, with over 30 years of experience and international presence.

• Brucellacapt®

  Solution for the diagnosis of chronic brucellosis, an international reference for chronic forms of Malta fever.

• AMPLIRUN®

  Line of molecular controls for PCR designed to improve precision, reliability and standardization of nucleic acid amplification techniques.

• VIRCELL REALTIME PCR kits

  Real-time PCR kits for differentiating tuberculosis and non-tuberculosis infections.

• Aspergillus galactomannan detection

  Automated detection to support early diagnosis of invasive aspergillosis in high-risk patients.

• Helicobacter pylori non-invasive diagnostic solutions

  Non-invasive solutions to support diagnosis and monitoring of Helicobacter pylori infection.

1. 1Vircell | Diagnóstico de enfermedades infecciosasvircell.com
2. 2Sobre Vircell | Empresa de biotecnología y diagnóstico in vitrovircell.com
3. 3Vircell Microbiologists (Spain) - Wikidatawikidata.org